BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37606641)

  • 1. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
    Casanova M; Bautista F; Campbell-Hewson Q; Makin G; Marshall LV; Verschuur AC; Cañete Nieto A; Corradini N; Ploeger BA; Brennan BJ; Mueller U; Zebger-Gong H; Chung JW; Geoerger B
    Clin Cancer Res; 2023 Nov; 29(21):4341-4351. PubMed ID: 37606641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
    Xu J; Xie L; Sun X; Liu K; Tang X; Yan T; Yang R; Guo W; Gu J
    Oncologist; 2021 Jul; 26(7):e1256-e1262. PubMed ID: 33611805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
    Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
    Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
    Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
    Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
    Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
    Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
    Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
    Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
    Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
    Dong S; Sun K; Xie L; Xu J; Sun X; Ren T; Huang Y; Yang R; Tang X; Yang F; Gu J; Guo W
    Medicine (Baltimore); 2021 Dec; 100(51):e28078. PubMed ID: 34941047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
    Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.